^
Association details:
| Biomarker: | EGFR L858R |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Vizimpro (dacomitinib) (pan-HER inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Bevacizumab plus dacomitinib combination therapy for L858R-mutated metastatic lung adenocarcinoma: A report of two cases
Published date:
03/27/2022
Excerpt:
A 73-year-old man visited our hospital...and was diagnosed with stage IV lung adenocarcinoma with L858R point mutation in exon 21….He received first-line therapy with dacomitinib (30 mg, daily) plus bevacizumab (7.5 mg/kg, every 3 weeks). The results of follow-up imaging performed after 3 months showed decreased primary tumor size in chest CT...and improved brain metastasis in brain MRI...
DOI:
https://doi.org/10.1111/1759-7714.14396
